Bioequivalence and Bioavailability Forum

Subject	Author	Posted	Rep.	last R.	Views
Requesting data for a publication 📥 ♻️ 🚀 📌	Helmut	2023-02-23 10:46	0		9,830
Group-by-Treatment Interaction: the final word?	Helmut	2024-04-19 01:26	0		241
Subject effect justification Subject effect justification	Dafni_C	2024-01-17 10:00	1	2024-01-17 12:30	939
Carry over and statistical adjustment in BE computations Carry-over → 🚮 Carry-over → 🚮 Carry-over → 🚮 Carry-over Carry-over Carry-over Carry-over Carry-over more than 20% subject carry over effect investigation carry over effect investigation based on what? carry over effect investigation based on what? Outdated and wrong answers Wrong answer	Achievwin	2023-10-02 20:34	13	2023-10-06 13:20	2,429
Calculation of PE and 90% CI No ‘R1’ and ‘R2’ in replicate designs No ‘R1’ and ‘R2’ in replicate designs Rose is a rose is a rose is a rose No ‘R1’ and ‘R2’ in replicate designs	Brus	2023-06-14 16:34	4	2023-06-19 19:42	1,591
within subject standard deviation in fully replicate design if carry over effect is present within subject standard deviation in fully replicate design if carry over effect is present within subject standard deviation in fully replicate design if carry over effect is present within subject standard deviation in fully replicate design if carry over effect is present within subject standard deviation in fully replicate design if carry over effect is present within subject standard deviation in fully replicate design if carry over effect is present	Ankit Parikh	2023-06-08 13:54	5	2023-06-14 10:37	1,632
average bioequivalence: MLE vs. REML average bioequivalence: MLE vs. REML average bioequivalence: MLE vs. REML average bioequivalence: MLE vs. REML	Mahmoud	2023-03-11 12:21	3	2023-03-16 23:51	1,897
Variance VS Coefficient of variation s² ↔ CV CV ≈ s for low variances CV ≈ s for low variances CV ≈ s for low variances	Imph	2023-02-27 09:09	4	2023-03-06 12:42	2,118
Pharmacokinetic and statistical analysis in bioequivalence while maintaining the blind Blinded NCA in Phoenix/WinNonlin Blinded NCA in Phoenix/WinNonlin Blinded NCA in Phoenix/WinNonlin Pharmacokinetic and statistical analysis in bioequivalence while maintaining the blind Phoenix: Locked Workflows Phoenix: Locked Workflows Blind forever? Blind forever?	Imph	2023-02-12 08:31	8	2023-02-15 11:00	2,469
Are Statistical Analysis Plans “required” for Pivotal Studies? SAP vs. part of the clinical protocol SAP vs. part of the clinical protocol Traceability Are Statistical Analysis Plans “required” for Pivotal Studies? Are Statistical Analysis Plans “required” for Pivotal Studies?	Sereng	2023-02-08 18:23	5	2023-02-16 06:55	2,621
How to calculate Within-subject variability in a replicated BE Models, models!	Brus	2022-12-25 09:21	1	2022-12-25 12:17	2,231
Confidence intervals Confidence intervals	Bebac user	2022-12-19 13:59	1	2022-12-21 21:11	2,346
Observations in a linear model Observations in a linear model Observations in a linear model Observations in a linear model And the Oscar goes to: Replicates! It's all in the df's	Helmut	2022-11-15 10:55	5	2022-11-18 17:28	2,854
Parameter affecting Subject by formulation	Mithu	2022-06-07 09:12	0		1,204
Defining time to concentration threshold Defining time to concentration threshold I prefer interpolation I prefer interpolation Continuous variable → mean	Cytokrom C	2022-04-29 16:24	4	2022-05-01 22:05	2,442